| Targeting the TGFβ pathway for cancer therapy C Neuzillet, A Tijeras-Raballand, R Cohen, J Cros, S Faivre, E Raymond, ... Pharmacology & therapeutics 147, 22-31, 2015 | 723 | 2015 |
| Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability–high gastric or esophagogastric junction … T André, D Tougeron, G Piessen, C de La Fouchardière, C Louvet, ... Journal of Clinical Oncology 41 (2), 255-265, 2023 | 254 | 2023 |
| Association of primary resistance to immune checkpoint inhibitors in metastatic colorectal cancer with misdiagnosis of microsatellite instability or mismatch repair deficiency … R Cohen, E Hain, O Buhard, A Guilloux, A Bardier, R Kaci, P Bertheau, ... JAMA oncology 5 (4), 551-555, 2019 | 248 | 2019 |
| Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment J Taieb, M Svrcek, R Cohen, D Basile, D Tougeron, JM Phelip European Journal of Cancer 175, 136-157, 2022 | 160 | 2022 |
| Microsatellite instability in patients with stage III colon cancer receiving fluoropyrimidine with or without oxaliplatin: an ACCENT pooled analysis of 12 adjuvant trials R Cohen, J Taieb, J Fiskum, G Yothers, R Goldberg, T Yoshino, S Alberts, ... Journal of Clinical Oncology 39 (6), 642-651, 2021 | 151 | 2021 |
| Targeting cancer cell metabolism in pancreatic adenocarcinoma R Cohen, C Neuzillet, A Tijeras-Raballand, S Faivre, A de Gramont, ... Oncotarget 6 (19), 16832, 2015 | 130 | 2015 |
| The balance between cytotoxic T-cell lymphocytes and immune checkpoint expression in the prognosis of colon tumors L Marisa, M Svrcek, A Collura, E Becht, P Cervera, K Wanherdrick, ... JNCI: Journal of the National Cancer Institute 110 (1), 68-77, 2018 | 127 | 2018 |
| Immunotherapy and patients treated for cancer with microsatellite instability R Colle, R Cohen, D Cochereau, A Duval, O Lascols, D Lopez-Trabada, ... Bulletin du cancer 104 (1), 42-51, 2017 | 117 | 2017 |
| MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors M Svrcek, O Lascols, R Cohen, A Collura, V Jonchère, JF Fléjou, ... Bulletin du cancer 106 (2), 119-128, 2019 | 108 | 2019 |
| Immune checkpoint inhibition in colorectal cancer: microsatellite instability and beyond R Cohen, B Rousseau, J Vidal, R Colle, LA Diaz, T André Targeted oncology 15, 11-24, 2020 | 100 | 2020 |
| Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency R Cohen, O Buhard, P Cervera, E Hain, S Dumont, A Bardier, JB Bachet, ... European Journal of Cancer 86, 266-274, 2017 | 90 | 2017 |
| Clinical validity of HPV circulating tumor DNA in advanced anal carcinoma: an ancillary study to the epitopes-HPV02 trial A Bernard-Tessier, E Jeannot, D Guenat, A Debernardi, M Michel, ... Clinical Cancer Research 25 (7), 2109-2115, 2019 | 87 | 2019 |
| Discordance between immunochemistry of mismatch repair proteins and molecular testing of microsatellite instability in colorectal cancer AGDA De Salins, G Tachon, R Cohen, L Karayan-Tapon, A Junca, ... ESMO Open 6 (3), 100120, 2021 | 78 | 2021 |
| Pathological tumor response following immune checkpoint blockade for deficient mismatch repair advanced colorectal cancer K Ludford, R Cohen, M Svrcek, WC Foo, R Colle, Y Parc, JV Thomas, ... JNCI: Journal of the National Cancer Institute, 2020 | 78 | 2020 |
| Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers G Fucà, R Cohen, S Lonardi, K Shitara, ME Elez, M Fakih, J Chao, ... Journal for Immunotherapy of Cancer 10 (2), 2022 | 76 | 2022 |
| Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study D Tougeron, B Sueur, A Zaanan, C de la Fouchardiére, D Sefrioui, ... International Journal of Cancer 147 (1), 285-296, 2020 | 75 | 2020 |
| RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal … R Cohen, J Bennouna, A Meurisse, C Tournigand, C De La Fouchardière, ... Journal for ImmunoTherapy of Cancer 8 (2), e001499, 2020 | 74 | 2020 |
| BRAF-Mutated Colorectal Cancer: What Is the Optimal Strategy for Treatment? R Cohen, P Cervera, M Svrcek, A Pellat, C Dreyer, A de Gramont, T André Current treatment options in oncology 18, 1-14, 2017 | 74 | 2017 |
| Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR) JF Delattre, R Cohen, J Henriques, A Falcoz, JF Emile, S Fratte, ... Journal of Clinical Oncology 38 (15), 1702-1710, 2020 | 70 | 2020 |
| Combining tumor deposits with the number of lymph node metastases to improve the prognostic accuracy in stage III colon cancer: a post hoc analysis of the CALGB/SWOG 80702 … R Cohen, Q Shi, J Meyers, Z Jin, M Svrcek, C Fuchs, F Couture, P Kuebler, ... Annals of Oncology 32 (10), 1267-1275, 2021 | 68 | 2021 |
Thierry AndréHôpital Saint AntoinePotvrđena adresa e-pošte na aphp.fr